An ever-increasing demand for novel antimicrobials to treat life-threatening infections
caused by the global spread of multidrug-resistant bacterial pathogens stands in stark …

The landscape of medical treatments is undergoing a transformative shift. Precision
medicine has ushered in a revolutionary era in healthcare by individualizing diagnostics and …

The optimal pharmacokinetic (PK) required for a drug candidate to elicit efficacy is highly
dependent on the targeted pharmacology, a relationship that is often not well characterized …

Urinary tract infections (UTIs) are very common disorders that affect adult women. Indeed,
50% of all women suffer from UTIs at least one time in their lifetime; 20–40% of them …

Historically, failure rates in drug development are high; increased sophistication and
investment throughout the process has shifted the reasons for attrition, but the overall …

Improved pharmacokinetics/pharmacodynamics (PK/PD) prediction in the early stages of
drug development is essential to inform lead optimization strategies and reduce attrition …

Avibactam is a novel non-β-lactam β-lactamase inhibitor that has been approved in the
United States and Europe for use in combination with ceftazidime. Combinations of …

The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum
hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen …

There is a substantial need for novel therapeutics to combat the widespread impact caused
by Crytosporidium infection. However, there is a lack of knowledge as to which drug …

The renin–angiotensin–aldosterone-systems (RAAS) play a central role in the
pathophysiology of congestive heart failure (CHF), justifying the use of angiotensin …